Keeping Up With The CGRPs: Alder Gains Momentum In A Tight Race
This article was originally published in The Pink Sheet Daily
Executive Summary
Alder released positive Phase IIb data testing its intravenous CGRP antibody March 28 as the race to bring a first-in-class product to market for the prevention of migraine intensifies.